Companies › CSPC Ouyi Pharmaceutical
5 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Metabolic and endocrine, Other, Psychiatry; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Prusogliptin Dipeptidyl peptidase-4 inhibitor | DPP4 | Phase 3 | Type 2 Diabetes | Nov 2026 |
| Dextromethorphan Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist | SIGMAR1, GRIN2A | Phase 3 | Major Depressive Disorder (MDD) | Dec 2026 |
| SYH2069 Injection | – | Phase 1 | Overweight or Obesity | Nov 2026 |
| SYH2082 Injection | – | Phase 1 | Overweight or Obesity | Dec 2026 |
| SYH9089 injection | – | Phase 1 | Postoperative Pain | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07026968 | Prusogliptin | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Nov 2026 |
| NCT07736391 | SYH2069 Injection | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Nov 2026 |
| NCT07736404 | SYH2082 Injection | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Dec 2026 |
| NCT06958692 | Dextromethorphan | Phase 3 | Major Depressive Disorder (MDD) | Psychiatry | Dec 2026 |
| NCT07519109 | SYH9089 injection | Phase 1 | Postoperative Pain | Other | Dec 2026 |
Beijing QL Biopharmaceutical Gan & Lee Pharmaceuticals. BrightGene Bio-Medical Technology JCR Pharmaceuticals BioMarin Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.